- Home
- CATX vs CHRS Comparison
CATX vs CHRS Comparison
Compare CATX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | CHRS |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.1M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CATX | CHRS |
|---|---|---|
| Price | $2.74 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $11.56 | $4.02 |
| AVG Volume (30 Days) | ★ 1.4M | 895.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | $1,075,000.00 | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.31 |
| P/E Ratio | ★ N/A | $2.70 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $1.60 | $0.71 |
| 52 Week High | $5.39 | $1.89 |
Technical Indicators
Market Signals| Indicator | CATX | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 58.50 |
| Support Level | $2.67 | $1.27 |
| Resistance Level | $2.88 | $1.43 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.44 | 75.00 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.